Wall Street brokerages expect Amyris Inc (NASDAQ:AMRS) to report earnings per share of ($0.17) for the current quarter, Zacks reports. Two analysts have provided estimates for Amyris’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.11). Amyris reported earnings per share of ($1.14) in the same quarter last year, which suggests a positive year-over-year growth rate of 85.1%. The firm is expected to issue its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Amyris will report full-year earnings of ($1.41) per share for the current fiscal year, with EPS estimates ranging from ($1.56) to ($1.26). For the next year, analysts forecast that the business will post earnings of $0.19 per share, with EPS estimates ranging from $0.16 to $0.22. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Amyris.
Amyris (NASDAQ:AMRS) last posted its earnings results on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). The firm had revenue of $24.81 million for the quarter, compared to the consensus estimate of $37.52 million. During the same period in the prior year, the business earned ($1.32) EPS. The company’s revenue was down 3.4% compared to the same quarter last year.
A number of research firms have recently issued reports on AMRS. HC Wainwright set a $15.00 target price on shares of Amyris and gave the company a “buy” rating in a research note on Thursday, August 30th. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. BidaskClub upgraded shares of Amyris from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Finally, ValuEngine upgraded shares of Amyris from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $9.13.
In related news, COO Eduardo Alvarez purchased 11,877 shares of the stock in a transaction that occurred on Wednesday, September 5th. The stock was acquired at an average price of $8.45 per share, with a total value of $100,360.65. Following the completion of the acquisition, the chief operating officer now directly owns 331,877 shares in the company, valued at approximately $2,804,360.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director L John Doerr sold 4,877,386 shares of the firm’s stock in a transaction that occurred on Friday, August 17th. The shares were sold at an average price of $6.22, for a total transaction of $30,337,340.92. Following the completion of the sale, the director now directly owns 5,532 shares of the company’s stock, valued at approximately $34,409.04. The disclosure for this sale can be found here. In the last three months, insiders purchased 50,877 shares of company stock valued at $393,161 and sold 8,824,625 shares valued at $54,897,886. Company insiders own 21.80% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Amyris in the first quarter valued at approximately $110,000. Millennium Management LLC acquired a new stake in shares of Amyris in the first quarter valued at approximately $1,643,000. Barclays PLC increased its holdings in shares of Amyris by 30,067.8% in the first quarter. Barclays PLC now owns 44,950 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 44,801 shares in the last quarter. BlackRock Inc. grew its holdings in Amyris by 139.2% during the 1st quarter. BlackRock Inc. now owns 53,414 shares of the biotechnology company’s stock worth $358,000 after acquiring an additional 31,083 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in Amyris during the 2nd quarter worth $413,000. 27.90% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:AMRS traded down $0.07 during trading on Monday, reaching $8.22. The stock had a trading volume of 807,134 shares, compared to its average volume of 1,179,053. Amyris has a 52 week low of $2.71 and a 52 week high of $9.22. The company has a current ratio of 0.42, a quick ratio of 0.38 and a debt-to-equity ratio of -0.24. The stock has a market capitalization of $417.55 million, a P/E ratio of -2.70 and a beta of 0.20.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.